Inhibition of osteoclast formation by 3-methylcholanthrene, a ligand for arylhydrocarbon receptor: suppression of osteoclast differentiation factor in osteogenic cells

Author： Naruse M.   Otsuka E.   Naruse M.   Ishihara Y.   Miyagawa-Tomita S.   Hagiwara H.  

Publisher： Elsevier

ISSN： 0006-2952

Source： Biochemical Pharmacology, Vol.67, Iss.1, 2004-01, pp. : 119-127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Advances in Osteoclast Differentiation and Function

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 5, Iss. 3, 2005-09 ,pp. : 347-355

Bentham Science Publishers

Access to resources Recommend Favorite

Osteoclast differentiation inhibitors: a patent review (2008 – 2012)

By Kim Seong Hwan   Moon Seong-Hee  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 12, 2013-12 ,pp. : 1591-1610

Informa Healthcare

Access to resources Recommend Favorite

Selective Inhibition of Osteoclast Vacuolar H+-ATPase

By  

Current Pharmaceutical Design, Vol. 8, Iss. 23, 2002-10 ,pp. : 2033-2048

Bentham Science Publishers

Access to resources Recommend Favorite

3'4'7-Trihydroxyflavone inhibits RANKL-induced osteoclast formation

By Kang Ju-Hee   Lee Juhyun   Moon Miran   Yim Mijung  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 10, 2015-10 ,pp. : 661-667

Govi-Verlag

Access to resources Recommend Favorite

In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation

By Baron R.   Tsouderos Y.  

European Journal of Pharmacology, Vol. 450, Iss. 1, 2002-08 ,pp. : 11-17

Elsevier

Access to resources Recommend Favorite